Pasithea Therapeutics Corp. filed a current report on Form 8-K on November 16, 2026, disclosing that on November 13, 2026, the company announced initial clinical data from its ongoing Phase 1/1b study of PAS-004 and received FDA clearance of an Investigational New Drug application for a Phase 2 trial of PAS-004.

Key Highlights

  • Phase 1/1b data presented: Pasithea Therapeutics disclosed initial clinical data from its ongoing Phase 1/1b study of PAS-004 in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas and cutaneous neurofibromas.
  • Conference presentation: The data were presented at the 2026 European Neurofibromatosis Conference, according to the filing.
  • FDA IND clearance: The U.S. Food and Drug Administration cleared the company's Investigational New Drug application for a Phase 2 trial of PAS-004 in adults with NF1-associated cutaneous neurofibromas.
  • Webcast posted: The company posted a webcast on November 13, 2026 to discuss the data, with a replay accessible at the URL noted in the filing.
  • Exchange listing: Common Stock (par value $0.0001 per share) is listed on the Nasdaq Capital Market under the ticker NASDAQ:KTTA.

Pasithea Therapeutics Reports PAS-004 Clinical Data and FDA Phase 2 IND Clearance

According to the Form 8-K filed November 16, 2026, Pasithea Therapeutics Corp. (NASDAQ:KTTA) issued a press release on November 13, 2026, announcing two developments related to its drug candidate PAS-004. The company disclosed initial clinical data from its ongoing Phase 1/1b study evaluating PAS-004 in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas and cutaneous neurofibromas. These data were presented at the 2026 European Neurofibromatosis Conference, the filing states.

The filing further reported that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application for a Phase 2 trial of PAS-004 specifically in adults with NF1-associated cutaneous neurofibromas. In connection with the press release, the company also posted a webcast on November 13, 2026, to discuss the data. A replay of that webcast is accessible at the link provided in the filing.

The information furnished under Item 7.01 and in Exhibit 99.1, the company noted, "shall not be deemed to be 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended." The report was signed by Tiago Reis Marques, Chief Executive Officer, on November 16, 2026. Pasithea Therapeutics is incorporated in Delaware, headquartered at 1111 Lincoln Road, Suite 500, Miami Beach, Florida, and is classified as an emerging growth company.

What Was Disclosed

The filing disclosed initial Phase 1/1b clinical data for PAS-004 in NF1-associated neurofibromas, presented at the 2026 European Neurofibromatosis Conference, alongside FDA clearance of an IND for a Phase 2 trial of PAS-004 in NF1-associated cutaneous neurofibromas.